STOCK TITAN

Scholar Rock Holding Corporation (SRRK) Stock News

SRRK NASDAQ

Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.

Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.

Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) announced that management will participate in investor conference fireside chats in Miami on December 1 and 2, 2026.

The 9th Annual Evercore Healthcare Conference chat is scheduled for December 1 at 8:45 a.m. ET. The Citi 2026 Global Healthcare Conference chat is scheduled for December 2 at 3:40 p.m. ET. Live webcasts will be available through the Events and Presentations page of the company’s investor website, with replays available for approximately 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
conferences
-
Rhea-AI Summary

Scholar Rock (SRRK) granted inducement equity awards covering 39,587 common shares to six newly hired employees under its 2022 Inducement Equity Plan.

The awards comprise options to purchase 11,349 shares and restricted stock units covering 28,238 shares. The options have a $51.55 exercise price, equal to the stock’s closing price on November 9, 2026. Options vest 25% on each employee’s first start-date anniversary, with the remaining 75% vesting in 12 equal quarterly installments. Restricted stock units vest in four equal annual installments. All vesting requires continued service through the applicable vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
-
Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) reported third-quarter 2026 results as its newly approved spinal muscular atrophy treatment ISEMBYLD entered the U.S. market. Net product revenue was $570,000, reflecting shipments to the specialty network; initial patients were infused in October. FDA approval on September 11 covers patients aged two and older currently receiving an SMN2-targeted treatment. Quarterly net loss widened to $107.239 million from $102.220 million, while loss per share narrowed to $0.81 from $0.90.

Cash, cash equivalents and marketable securities totaled $413.599 million at September 30. A November agreement to sell a priority review voucher for $205 million awaits closing, including expiration of the antitrust waiting period. European review of apitegromab is underway, with the company expecting an opinion in H1 2027; Japan accepted its application for priority review. Clinical development continues across additional programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.89%
Tags
Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) management will participate in investor conference fireside chats in London on November 16 and 17, 2026. The UBS Global Biopharma Conference chat is scheduled for 10:00 a.m. GMT / 5:00 a.m. ET on November 16. The Jefferies Global Healthcare Conference chat is scheduled for 4:00 p.m. GMT / 11:00 a.m. ET on November 17. Live webcasts will be available on the company’s investor website, with replays available for approximately 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
-
Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) will report third quarter 2026 financial results on November 10, 2026, before financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET. An archived webcast replay will be available on the company’s website for approximately 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
earnings date
-
Rhea-AI Summary

Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 61,020 common shares to seven newly hired employees.

The awards comprise options to purchase 17,461 shares and restricted stock units covering 43,559 shares. The options have a $41.94 exercise price, equal to the stock’s closing price on October 12, 2026. The grants fall under the company’s 2022 Inducement Equity Plan and Nasdaq Listing Rule 5635(c)(4). All vesting requires continued employee service through the applicable vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
Rhea-AI Summary

Scholar Rock (SRRK) has resubmitted its European marketing application for apitegromab to treat children and adults with spinal muscular atrophy.

The application replaces the Catalent Indiana facility with an alternate facility for filling and finishing doses, following dialogue with the European Medicines Agency. The same site supported the September 11, 2026 U.S. approval of ISEMBYLD, the brand name for apitegromab. Scholar Rock anticipates an opinion from the agency's Committee for Medicinal Products for Human Use in the first half of 2027. The U.S. launch is underway. In the Phase 3 SAPPHIRE trial, apitegromab recipients showed motor function improvement after one year, while patients receiving only an SMN2-targeted treatment lost motor function.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Scholar Rock (SRRK) granted inducement equity awards covering 83,102 shares of common stock to ten newly hired employees under its 2022 Inducement Equity Plan, in line with Nasdaq Listing Rule 5635(c)(4).

The grants consist of stock options for 23,801 shares and restricted stock units (RSUs) for 59,301 shares. The stock options have an exercise price of $51.85, equal to the closing price on September 14, 2026. Options vest 25% on the first anniversary of each employee’s start date with the remaining 75% vesting in 12 equal quarterly installments. RSUs vest in four equal annual installments, and all awards require continued service through each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
Rhea-AI Summary

Scholar Rock (SRRK) received FDA approval for ISEMBYLD (apitegromab-mstn) on September 11, 2026, as the first and only muscle-targeted treatment for spinal muscular atrophy (SMA) in adults and children ≥2 years who are already on an SMN2-targeted therapy.

Approval is based on the Phase 3 SAPPHIRE trial, where the recommended 10 mg/kg dose achieved a 2.2‑point mean HFMSE motor-function improvement versus SMN2 therapy alone at one year (nominal p = 0.0121; ages 2–12, n = 103). A ≥3‑point HFMSE gain occurred in 34.2% of ISEMBYLD patients vs. 13.5% on placebo (odds ratio 3.8; nominal p = 0.0125). The safety database includes 500+ individuals, with most SAPPHIRE participants entering the ONYX extension. The most common adverse reactions were respiratory and viral infections, vomiting, cough, headache, gastroenteritis, pharyngitis, hypersensitivity, and a higher fracture rate (9% vs. 2% placebo).

U.S. commercial launch is underway, product will ship in the coming days, and the company has been granted a Rare Pediatric Disease Priority Review Voucher. The Scholar Rock Supports™ program is active to assist with access, reimbursement, and infusion logistics, including hospital, home, or infusion-center administration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
Rhea-AI Summary

Scholar Rock (SRRK) received FDA Fast Track and Orphan Drug designations for apitegromab in facioscapulohumeral muscular dystrophy (FSHD) and has begun dosing participants in the Phase 2 FORGE trial. Apitegromab is an investigational fully human monoclonal antibody designed to inhibit myostatin activation in skeletal muscle.

FORGE is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study in approximately 60 adults with genetically confirmed FSHD, randomized 1:1 to apitegromab 10 mg/kg or placebo, administered intravenously every four weeks for 52 weeks. The primary endpoint is percent change from baseline in total lean muscle volume by MRI at Week 52, with secondary endpoints including lean muscle volume at Week 24, changes in muscle fat fraction, and safety and tolerability. The FSHD program is supported by translational preclinical data in a mouse model showing increased muscle mass, strength, and endurance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags

FAQ

What is the current stock price of Scholar Rock Holding (SRRK)?

Scholar Rock Holding (SRRK) last closed at $48.00.

What is the market cap of Scholar Rock Holding (SRRK)?

The market cap of Scholar Rock Holding (SRRK) is approximately $5.9B.